Sima Aman, NP
Nurse Practitioner · Anaheim
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
- Since medical school
- 4 years
- Graduated 2022
Offices
1 location · Mental Health and Nursing PC · 10 clinicians in this group
Looking this up.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Sima Aman’s office at (714) 361-0898 to ask if they take your plan before you enroll.
Original Medicare doctor bills
$9,676
Medicare paid this office $9,676 for 15 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 11 | $5,231 | $68 |
| Psychotherapy with evaluation and management visit, 30 minutes | 13 | $3,523 | $44 |
Who their Medicare patients are
15 Original Medicare patients in 2024. Average age 64 · 85 and older 0% · Health risk score 1.17. At or below the middle of the specialty; the typical nurse practitioner clinician is at 1.42.
Conditions among them: Depression 75%.
The office billed $23,460, Medicare allowed $12,646 and paid $9,676; for 167 services of 5 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Medicaid work
$89,724 in 2024
Medicaid paid $89,724 for 927 billed services this clinician did in 2024, up to 96 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 349 | $41,472 |
| Psychotherapy, 30 minutes with patient when performed with an evaluation and management service (List separately in addition to the code for primary procedure) | 462 | $27,104 |
| New patient visit (45+ min) | 116 | $21,149 |
| 2024 | 927 | 3 | 96 | $89,724 |
Drugs they prescribed that Part D paid
$11,102
Pharmacies billed $11,102 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 399) in 2024. At or below the middle of the specialty; the typical nurse practitioner clinician is at 0%.
396 generic and fewer than 11 brand-name prescriptions · $11,102 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Haloperidol Decanoate | 13 | $859 | $66 |
| Chlorpromazine | 12 | $783 | $65 |
| Temazepam | 11 | $620 | $56 |
| Bupropion Xl | 27 | $416 | $15 |
| Duloxetine | 15 | $409 | $27 |
See all 17 drugs
| Haloperidol Decanoate | 13 | $859 | $66 |
| Chlorpromazine | 12 | $783 | $65 |
| Temazepam | 11 | $620 | $56 |
| Bupropion Xl | 27 | $416 | $15 |
| Duloxetine | 15 | $409 | $27 |
| Buspirone | 28 | $393 | $14 |
| Haloperidol | 26 | $209 | $8 |
| Venlafaxine Hcl Er | 22 | $168 | $8 |
| Hydroxyzine Pamoate | 18 | $168 | $9 |
| Mirtazapine | 15 | $145 | $10 |
| Olanzapine | 25 | $135 | $5 |
| Fluoxetine | 35 | $118 | $3 |
| Gabapentin | 16 | $81 | $5 |
| Alprazolam | 19 | $59 | $3 |
| Paroxetine | 14 | $39 | $3 |
| Trazodone | 19 | $22 | $1 |
| Sertraline | 17 | $13 | $1 |
Year by year
| 2024 | 399 | 28 | 0% (0) | None | $11,102 |
| 2023 | 79 | 11 | 0% (0) | None | $7,245 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 1 drug
| Buspirone | 17 | $186 | $11 |
Money from drug and device companies
$894 in 2025
| 2025 | 13 | 37 | None | $894 |
| 2024 | 12 | 49 | None | $1,236 |
| 2023 | 13 | 56 | None | $1,300 |
| 2022 | 1 | 1 | None | $100 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Janssen Pharmaceuticals | Invega Sustenna | $185 | 7 payments
|
| Otsuka America Pharmaceutical | Rexulti | $184 | 7 payments
|
| Neurocrine BioSciences | Ingrezza | $107 | 3 payments
|
| Vanda Pharmaceuticals | Fanapt | $106 | 4 payments
|
| Abbvie | Vraylar | $68 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Cobenfy | $56 | 2 payments
|
See all 37 published payments
| Vanda Pharmaceuticals | Meals · 2025-12-18 | Fanapt | $23 |
| Abbvie | Meals · 2025-12-12 | Vraylar | $14 |
| Janssen Pharmaceuticals | Meals · 2025-11-13 | Invega Sustenna | $35 |
| Tris Pharma | Meals · 2025-11-04 | Dyanavel Xr | $18 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-10-30 | Cobenfy | $27 |
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Meals · 2025-10-15 | Caplyta | $14 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-25 | Cobenfy | $29 |
| Otsuka America Pharmaceutical | Meals · 2025-09-24 | Rexulti | $35 |
| Supernus Pharmaceuticals | Meals · 2025-09-15 | Qelbree | $14 |
| Neurocrine BioSciences | Meals · 2025-09-04 | Ingrezza | $32 |
| Abbvie | Meals · 2025-08-29 | Vraylar | $21 |
| Otsuka America Pharmaceutical | Meals · 2025-08-21 | Rexulti | $33 |
| Janssen Pharmaceuticals | Meals · 2025-07-31 | Invega Sustenna | $37 |
| Janssen Pharmaceuticals | Meals · 2025-07-01 | Invega Sustenna | $31 |
| Janssen Pharmaceuticals | Meals · 2025-07-01 | Invega Sustenna | $2 |
| Vanda Pharmaceuticals | Meals · 2025-06-19 | Fanapt | $31 |
| Otsuka America Pharmaceutical | Meals · 2025-06-18 | Rexulti | $19 |
| Vanda Pharmaceuticals | Meals · 2025-06-12 | Fanapt | $28 |
| Janssen Pharmaceuticals | Meals · 2025-06-05 | Spravato | $37 |
| Axsome Therapeutics | Meals · 2025-06-05 | Auvelity | $25 |
| Janssen Pharmaceuticals | Meals · 2025-05-28 | Invega Sustenna | $10 |
| Otsuka America Pharmaceutical | Meals · 2025-05-22 | Rexulti | $29 |
| Neurocrine BioSciences | Meals · 2025-05-14 | Ingrezza | $37 |
| Corium | Meals · 2025-05-08 | Azstarys | $21 |
| Abbvie | Meals · 2025-05-02 | Vraylar | $15 |
| Otsuka America Pharmaceutical | Meals · 2025-04-24 | Rexulti | $29 |
| Tris Pharma | Meals · 2025-04-09 | Dyanavel Xr | $16 |
| Axsome Therapeutics | Meals · 2025-04-03 | Auvelity | $21 |
| Otsuka America Pharmaceutical | Meals · 2025-03-05 | Rexulti | $17 |
| Abbvie | Meals · 2025-02-28 | Vraylar | $19 |
| Supernus Pharmaceuticals | Meals · 2025-02-27 | Qelbree | $14 |
| Alkermes | Meals · 2025-02-20 | Aristada | $15 |
| Vanda Pharmaceuticals | Meals · 2025-02-12 | Fanapt | $24 |
| Otsuka America Pharmaceutical | Meals · 2025-02-06 | Rexulti | $23 |
| Janssen Pharmaceuticals | Meals · 2025-02-05 | Spravato | $33 |
| Neurocrine BioSciences | Meals · 2025-01-30 | Ingrezza | $38 |
| Lundbeck | Meals · 2025-01-15 | Rexulti | $29 |
See earlier years (2024, 2023, 2022)
2024: $1,236
| Abbvie | Vraylar | $311 | 11 payments
|
| Janssen Pharmaceuticals | Invega Sustenna | $178 | 6 payments
|
| Alkermes | Aristada | $165 | 7 payments
|
| Almatica Pharma | Loreev Xr | $140 | 5 payments
|
| Otsuka America Pharmaceutical | Abilify Maintena | $97 | 4 payments
|
| Vanda Pharmaceuticals | Fanapt | $74 | 3 payments
|
| Corium | Azstarys | $71 | 3 payments
|
| Neurocrine Biosciences | Ingrezza | $51 | 2 payments
|
| Lundbeck | Rexulti | $50 | 3 payments
|
| ITI Inc. (d/b/a Intra-Cellular Therapies Inc.) | Caplyta | $47 | 3 payments
|
| Supernus Pharmaceuticals | Qelbree | $31 | 1 payment
|
| Teva Pharmaceuticals USA | Uzedy | $22 | 1 payment
|
2023: $1,300
| Abbvie | Vraylar | $277 | 7 payments
|
| Indivior | Perseris | $205 | 8 payments
|
| Alkermes | Aristada | $201 | 8 payments
|
| Iti | Caplyta | $150 | 12 payments
|
| Lundbeck | Rexulti | $141 | 8 payments
|
| Neurocrine Biosciences | Ingrezza | $78 | 3 payments
|
| Axsome Therapeutics | Auvelity | $67 | 2 payments
|
| Teva Pharmaceuticals USA | Uzedy | $48 | 2 payments
|
| Janssen Pharmaceuticals | Invega Sustenna | $38 | 1 payment
|
| Almatica Pharma | Sertraline Hcl | $38 | 2 payments
|
| Corium | Azstarys | $20 | 1 payment
|
| Vanda Pharmaceuticals | Fanapt | $19 | 1 payment
|
| Neuronetics | Neurostar Tms Therapy System | $16 | 1 payment
|
2022: $100
| Otsuka Pharmaceutical Development & Commercialization | Jynarque | $100 | 1 payment
|
Professional record
- NPI
- 1689396293
- Licence
- CA 95022067
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Federal specialty code 363LP0808X (363LP0808X)
- Mailing address
- 14541 Delano St, Van Nuys, CA, 91411
- NPI first listed
- 2022-09-12
- NPI last updated
- 2023-03-01
- NPI record certified
- 2023-02-27
This is when the NPI record was last certified, not a medical board exam.